Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

269
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
269
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Performance of plasma pTau217, pTau181 and their ratios to Aβ42 in detecting Aβ pathology using a China-developed direct chemiluminescence assay.

Alzheimer's research & therapy·2026
Same author

Structural brain differences in major depressive disorder patients with suicidal risk: Evidence from the DIRECT consortium.

Journal of affective disorders·2026
Same author

Brain Network Controllability and Its Regional Gene Expression Profile Associated With Suicidal Tendencies in Major Depressive Disorder Patients.

Depression and anxiety·2025
Same author

Beyond Amyloid: Stem Cell Therapy Targets Neurodegeneration in Alzheimer's Disease.

Neuroscience bulletin·2025
Same author

Clinical Reasoning: A 59-Year-Old Female Patient With Urinary Dysfunction and Lightheadedness.

Neurology·2025
Same author

α-Synuclein Pathology from Kidney to Brain in Parkinson's Disease.

Neuroscience bulletin·2025
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Ver todos los artículos relacionados
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Desarrollo de fármacos

Jiong Shi1, Yun Xu2, Shenyu Zhao3

  • 1The First Affiliated Hospital of USTC, Hefei, anhui, China.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
Resumen
Este resumen es generado por máquina.

SHR-1707, un anticuerpo dirigido contra la proteína precursora amiloide beta, se está evaluando para determinar su eficacia y seguridad a largo plazo en pacientes con Alzheimer. Este ensayo de Fase 2 evaluará su impacto en la deposición de amiloide y la función cognitiva durante 78 semanas.

Palabras clave:
Alzheimeranticuerpo monoclonalproteína precursora amiloide betadesarrollo de fármacosensayo clínico

Más Videos Relacionados

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

Videos de Experimentos Relacionados

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

Área de la Ciencia:

  • Neurología; Inmunología; Farmacología

Sus antecedentes:

  • SHR-1707 es un anticuerpo monoclonal IgG1 humanizado dirigido contra la proteína precursora amiloide beta (Aβ) con afinidad demostrada in vitro por las especies de Aβ y eficacia in vivo en un modelo de ratón de la enfermedad de Alzheimer (EA).; Los estudios de Fase 1 indicaron que SHR-1707 es seguro y bien tolerado en adultos sanos y sujetos de edad avanzada.; Un ensayo de Fase 1b mostró que SHR-1707 fue generalmente bien tolerado en pacientes con deterioro cognitivo leve (DCL) debido a EA o EA leve, reduciendo la amiloide de manera dependiente de la dosis.

Objetivo del estudio:

  • Investigar la eficacia y seguridad a largo plazo de SHR-1707 en pacientes con deterioro cognitivo leve (DCL) debido a la enfermedad de Alzheimer (EA) o EA leve.; Evaluar el efecto de SHR-1707 en la deposición de Aβ cerebral durante 78 semanas.; Evaluar la seguridad y tolerabilidad de SHR-1707 durante un período de tratamiento extendido.

Principales métodos:

  • Un estudio aleatorizado, doble ciego, controlado con placebo de Fase 2 (NCT06199037) que involucra a pacientes de 50 a 85 años con DCL debido a EA o EA leve.; Los participantes fueron aleatorizados (2:1) para recibir SHR-1707 intravenoso (10 mg/kg Q2W) o placebo durante 26 semanas, estratificados por el estado de ApoE ε4.; Una extensión de etiqueta abierta permitió el tratamiento continuo con SHR-1707 durante 52 semanas, con el objetivo principal de evaluar el cambio en la deposición de Aβ cerebral mediante imágenes PET en la Semana 26.

Principales resultados:

  • El estudio está actualmente en curso en China.; Se anticipan resultados preliminares en el segundo trimestre de 2025.

Conclusiones:

  • El estudio de Fase 2 en curso tiene como objetivo proporcionar datos cruciales sobre el potencial terapéutico a largo plazo de SHR-1707.; Los hallazgos dilucidarán el impacto sostenido de SHR-1707 en la patología amiloide y los resultados clínicos en pacientes con EA.